Update on clindamycin: New pharmacokinetic and pharmacodynamic data

Infections in Medicine

Volumn 15, Issue 10, 1998, Pages 726-731

  Lewis, Russell E ^a   Klepser, Michael E ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTETAN; CEFOXITIN; CEFTIZOXIME; CHLORAMPHENICOL; CLINDAMYCIN; ERYTHROMYCIN; METRIC; METRO; METRONIDAZOLE; UNCLASSIFIED DRUG;

ANAEROBIC INFECTION; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTEROIDES; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; REVIEW; STREPTOCOCCUS INFECTION;

EID: 0031787295     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Ebert SC, Craig WA: Pharmacodynamic properties of antibiotics: Application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol 6:319-326, 1990.
2. American Society of Health System Pharmacists (ASHP): American Hospital Formulary Service Drug Information, 1997. Bethesda, Md., ASHP, pp-383-393.
3. Pharmacia & Upjohn: Cleocin Phosphate package insert. 1996. Pharmacia & Upjohn.
4. Lefrock JL, Abdolghader, Prince RA: Clindamycin. Med Clin N Am 66:1:103-122, 1982.
5. Fass RJ, Sholand JF, Hodges GR et al: Clindamycin in the treatment of anaerobic infections. Ann Intern Med 78:853-859, 1973.
6. Ameer B, Sesin P, Karchner AW: Selecting clindamycin dosage regimens. Am J Hosp Pharm 44:2027-2028, 1987.
7. Townsend RJ, Baker R: Pharmacokinetic comparison of three clindamycin phosphate dosage schedules: Drug Intell Clin Pharm 21:279-281, 1987.
8. Chin A, Gill MA, Ito MK, et al: Evaluation of two different clindamycin dosage regimens. Ther Drug Monit 11:421-424, 1989.
9. Plaisance KI, Drusano GL, Forrest A, et al: Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother 33:618-620, 1989.
10. Flaherty JF, Rodoni LC, Guglielmo J, et al: Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosage regimens. Antimicrob Agents Chemother 32:1825-1829, 1988.
11. Rovers JP, Ilersich AL, Einarson TR: Meta-analysis of parenteral clindamycin dosing regimens. Ann Pharmacother 29:852-858, 1995.
12. Buchwald D, Soumerai S, Vandevanter N, et al: Effect of hospitalwide change in clindamycin dosing schedule on clinical outcome. Rev Infect Dis 4:619-624, 1989.
13. Craig W: Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur J Clin Microbiol Infect Dis Supp 1:6-8, 1993.
14. Aldridge KE, Stratton CW: Bactericidal activity of ceftizoxime, cefotetan, and clindamycin against cefoxitan-resistant strains of the Bacteroides fragilis group. J Antimicrob Chemother 28:701-705, 1991.
15. Aldridge KE, Gelfand M, Reller LB, et al: A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamycins, penicillins, clindamycin, and metronidazole in the United States. Diagn Microbiol Infect Dis 18:235-241, 1994.
16. Klepser ME, Banevicius MA, Quintilliani R, et al: Characterization of bacterial activity of clindamycin against Bacteroides fragilis via kill curve methods. Antimicrob Agents Chemother 40:1941-944, 1996.
17. Turnidge JD: Prediction of antibiotic dosing intervals form in vitro susceptibility, pharmacokinetics, and post-antibiotic effect: Theoretical considerations. Scand J Infect Dis Suppl 74:137-141, 1990.
18. Xue IB, Davey PG, Phillips G: Variation in postantibiotic effect of clindamycin against clinical isolates of Staphylococcus aureus and implications for dosing of patients with osteomyelitis. Antimicrob Agents Chemother 40:1403-1407, 1996.
19. Klepser ME, Nicolau DP, Quintilliani R, et al: Bactericidal activity of low-dose clindamycin administered at 8- and 12-hour intervals against Staphylococcus aureus. Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob Agents Chemother 41:630-635, 1997.
20. Craig W: Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 22:89-96, 1995.
21. Leclercq R, Courvalin P: Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 35:1267-1272, 1991.
22. Leclercq R, Courvalin P: Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria. Antimicrob Agents Chemother 35:1273-1276, 1991.
23. Rasmussen BA, Bush K, Tally FP: Antimicrobial resistance in anaerobes. Clin Infect Dis 24(suppl 1):S110-S120, 1997.
24. Courvalin P, Ounissi H, Arthur M: Multiplicity of macrolide-lincosamide-streptogramin antibiotic resistance determinants. J Antimicrob Chemother 16(suppl A):S91-S100, 1985.
25. Sanchez ML, Flint KK, Jones RN: Occurrence of macrolide-lincosamide-streptogramin resistances among staphylococcal clinical isolates at a university medical center. Diagn Microbiol Infect Dis 16:205-213, 1993.
26. Jones RN, Cormican MG, Wanger A: Clindamycin resistance among erythromycin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 25:201-204, 1996.
27. McCracken GH: Emergence of resistant Streptococcus pneumoniae: A problem in pediatrics. Pediatr Infect Dis J 14:424-428, 1995.
28. Friedland IR, McCracken GH: Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 331:377-382, 1994.
29. Bisno AL, Stevens DL: Streptococcal infections of skin and soft tissue. N Engl J Med 334:240-245, 1996.
30. Eagle H: Experimental approach to the problem of treatment failure with penicillin in group A streptococcal infection in mice. Am J Med 13:389-399, 1952.
31. Stevens DL, Yan S, Bryant AE: Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: An explanation for the inoculum effect. J Infect Dis 167:1401-1405, 1993.
32. Stevens DL, Bryant AE, Yan S: Invasive group A streptococcal infection: New concepts in antibiotic treatment. Int J Antimicrob Agents 4:297-301, 1994.
33. Stevens DL, Gibbons AE, Bergstrom R, et al: The Eagle effect revisited: Efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 158:23-28, 1988.
34. Stevens DL, Maier KA, Mitten JE: Effect of antibiotics on toxin production and viability of Clostridium perfringes. Antimicrob Agents Chemother 31:213-218, 1987.
35. Stevens DL, Bryant AE, Hackett SP: Antibiotic effects on bacterial viability, toxin production, and host response. Clin Infect Dis 120(suppl 2):S154-S157, 1995.
36. Gemmell CG, Peterson PK, Schmeling D, et al: Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 67:1249-1256, 1981.
37. Milatovic D, Braveny I, Verhoef J: Clindamycin enhances opsonization of Staphylococcus aureus. Antimicrob Agents Chemother 24:413-417, 1983.
38. Veringa EM, Verhoef J: Clindamycin at subinhibitory concentrations enhances antibody- and complement-dependent phagocytosis by human polymorphonuclear leukocytes of Staphylococcus aureus. Chemotherapy 33:243-249, 1987.
39. Brook I, Gober AE, Leyva F: In vitro and in vivo effects of penicillin and clindamycin on expression of group A beta-hemolytic streptococcal capsule. Antimicrob Agents Chemother 39:1565-1568, 1995.